Mayukh Sukhatme, Director, President & Chief Investment Officer, on August 19, 2026, sold 335,174 shares in Roivant Sciences (ROIV) for $12,360,813. Following the Form 4 filing with the SEC, Sukhatme has control over a total of 18,630,739 common shares of the company, with 18,630,739 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1635088/000114036126034066/xslF345X05/form4.xml